PHARMACY

Impax names new generics division president

BY David Salazar
HAYWARD, Calif. — Impax Laboratories on Monday announced the appointment of Douglas S. Boothe to the position of president of its generics division. Boothe will report directly to the specialty pharmaceutical company’s CEO and oversee its entire generics business. 
 
“Doug is an accomplished executive with extensive generic pharmaceutical leadership and business development experience that will be instrumental in growing our generics business,” Impax president and CEO Fred Wilkinson said. “We are delighted that Doug is joining the company at an important time, as we expand our generics portfolio through the pending acquisition of products from Teva Pharmaceutical Industries and affiliates of Allergan, and prepare the strategies to maximize the return from our near term potential ANDA (abbreviated new drug application) approvals.”
 
Boothe had previously served as Perrigo’s EVP and general manager, where he was responsible for U.S. pharmaceuticals, including generics and specialty. From August 2008 to December 2012, he was CEO of Actavis after serving as EVP and COO for two years. Recently, he was a director of the Generic Pharmaceutical Associaton. 
 
keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
PHARMACY

Mylan launches its Crestor generic

BY David Salazar
PITTSBURGH —  Mylan last week launched its generic version of AstraZeneca’s Crestor (rosuvastatin calcium) tablets. The drug is indicated to treat high triglycerides in adults. 
 
Mylan’s generic will be available in 5-, 10-, 20- and 40-mg dosage strengths. For the 12 months ended May 31, the product had U.S. sales of $6.7 billion. 
 
keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
PHARMACY

Apotex launches generic version of AstraZeneca’s Crestor

BY Gina Acosta

WESTON, Fla. — Apotex  has launched rosuvastatin calcium tablets, the generic equivalent of Crestor by AstraZeneca.

Apotex's rosuvastatin calcium tablets are now available in 5mg, 10mg, 20mg and 40mg strengths.

According to IMS Health, Crestor had approximately $6.6 billion in sales in the 12 months ending in January 2016.
 

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?